Core Viewpoint - The article discusses the controversy surrounding "Antarctic krill oil" products linked to Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., which has led to regulatory investigations and significant brand management actions by the company [1][5][9]. Group 1: Regulatory Actions - The Chengdu New District Market Supervision Administration has established a joint investigation team to look into the "Antarctic krill oil" incident, with the case currently under investigation [1]. - The company has been ordered to stop the sale of the implicated products and is required to compensate consumers as per regulatory guidelines [5]. Group 2: Company Response - Beijing Tongrentang Group issued an apology for the damage caused to consumers and initiated a zero-tolerance brand management action, including a comprehensive investigation of the involved products [5]. - The company is pursuing legal action against the involved parties for trademark infringement and misleading consumers regarding the use of the "Beijing Tongrentang" name [9]. Group 3: Product Quality Concerns - A product marketed as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" was found to have a phospholipid content of 0, raising concerns about product authenticity [7]. - The product was not directly produced by Beijing Tongrentang but was distributed by its subsidiary, which has been criticized for its brand management and quality control practices [9]. Group 4: Brand Reputation - Beijing Tongrentang, a historic brand established in 1669, has faced multiple trust crises due to issues related to brand licensing and quality control of its subsidiary products [9].

Core Viewpoint - Tongrentang Group has issued an apology regarding the recent controversy over "Antarctic krill oil," acknowledging the damage caused to consumer rights and committing to a zero-tolerance approach towards brand management [1] Group 1: Company Response - Tongrentang Group has initiated a special action for strict brand management, deploying a task force to Sichuan for a comprehensive investigation of the involved products [1] - The company has ordered the immediate removal of the implicated products from the market and is ensuring compliance with regulatory requirements for consumer compensation [1] - Legal actions will be pursued against Sichuan Health, Habao Pharmaceutical, and related e-commerce platforms for trademark infringement and misleading consumers [1] Group 2: Product Investigation - The Shanghai Consumer Protection Committee conducted tests on 15 popular Antarctic krill oil products, revealing that the "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" had a phospholipid content of 0, indicating potential fraud [3] - The implicated product was not directly produced by Beijing Tongrentang but was distributed by its subsidiary, Sichuan Health Pharmaceutical, with manufacturing outsourced to Habao Pharmaceutical [5] Group 3: Brand Management Issues - Habao Pharmaceutical admitted to not adding the claimed "Antarctic krill oil" during production, and the product packaging was created per the requirements of Sichuan Health Pharmaceutical [5] - The unauthorized use of the "Beijing Tongrentang" name on the product has led to legal proceedings initiated by the company against the involved parties [5] - There are concerns within the industry regarding Tongrentang's brand authorization management and quality control of its subsidiary products, which have contributed to a decline in consumer trust [6]